StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.15 | $1.15 | +0.00% | 5.5M |
| 05-12 | $1.17 | $1.18 | +0.85% | 4.6M |
| 05-13 | $1.17 | $1.18 | +0.85% | 4.1M |
| 05-14 | $1.17 | $1.13 | -3.42% | 4.1M |
| 05-15 | $1.14 | $1.06 | -7.02% | 4.8M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $53.54M | $236.20M | $178.57M | $119.81M |
Operating Income | $-4.70M | $23.50M | $32.05M | $27.60M |
Net Income | $-9.05M | $-5.34M | $6.90M | $247.00K |
EPS (Diluted) | $-0.03 | $-0.02 | $0.03 | $0.02 |
Total Assets | $362.52M | $376.56M | $364.15M | $345.60M |
Total Liabilities | $335.14M | $343.95M | $322.56M | $316.37M |
Cash & Equivalents | $162.64M | $184.84M | $166.44M | $137.31M |
Free Cash Flow OCF − CapEx | $-21.27M | $67.70M | $36.64M | $8.61M |
Shares Outstanding | 267.90M | 265.42M | 265.23M | 263.04M |
No sell-side coverage available for AKBA.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for AKBA.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.